Assessing the BD landscape for in-licensing & acquisition deals in GI
Challenge:
A private equity client assessing a major investment asked Alacrita to research and assess the business development landscape for potential in-licensing or acquisition deals that could be value-enhancing add-ons to the target company, specifically in the GI space.
Solution:
Alacrita conducted a comprehensive search of late stage and commercial assets that had a good fit with the target company's therapeutic focus. We generated a long list of potential opportunities and, based on iterative discussions with our PE client, we filtered the database to yield a short list of 20 potential opportunities that represented the best combination of fit and potential availability. In addition, we generated a long list of other opportunities in adjacent areas for further consideration.
Business Development
We have deep experience on both the buy and sell-side, and work with our clients to ensure that partnership, licensing and investment decisions are taken with confidence, along with clear alignment between transaction price and asset value.
Related Case Studies
Explore similar engagements and see how we've helped other clients achieve their goals.
Scouting for assets discontinued from development due to neutralizing antibodies (Nabs)
Asset scouting for novel injectable formulations for large pharma
In-Licensing Support and Asset Scouting in CNS
Scouting for autoimmune / auto-inflammatory assets
Interested in Learning More?
Contact us to discuss how we can support your project with similar expertise.